CDNA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
CareDx Inc (CDNA) is not a strong buy for a beginner, long-term investor at this time. While the company has shown strong revenue growth and promising product developments, the financial performance, technical indicators, and mixed analyst sentiment suggest a cautious approach. Regulatory risks and declining profitability further add to the uncertainty.
The MACD histogram is negative (-0.143) but contracting, RSI is neutral at 42.334, and moving averages are converging. Key support is at 17.612, and resistance is at 20.087. Overall, the technical indicators suggest a neutral trend with no clear buy signal.
Q4 2025 revenue increased by 25% YoY, driven by strong growth in kidney testing services.
Launch of AlloHeme, an AI-powered solution for early relapse detection, set for
Revenue guidance for 2026 exceeds Street estimates.
Appointment of a new CFO with extensive financial management experience.
Non-GAAP EPS missed forecasts by $0.
Net income dropped by 105.27% YoY in Q4
Regulatory risks related to LCD policy remain unresolved.
Analyst sentiment is mixed, with one downgrade and concerns over long-term growth.
In Q4 2025, revenue increased by 25.19% YoY to $108.4 million. However, net income dropped by 105.27% YoY to -$4.1 million, and EPS fell by 107.14% YoY to -$0.08. Gross margin slightly declined to 67.24%.
BTIG raised the price target to $26 and maintains a Buy rating, citing the stock as undervalued. However, Craig-Hallum downgraded the stock to Hold, citing risks related to the LCD policy and less compelling risk-reward. Wells Fargo raised the price target to $18 but maintains an Equal Weight rating.
